Positive Outlook on Centessa Pharmaceuticals Driven by ORX750’s Promising Potential and Market Growth

Centessa Pharmaceuticals (CNTA) has received a new Buy rating, initiated by Needham analyst, Ami Fadia.

Ami Fadia’s rating is based on several compelling factors. Firstly, the potential of ORX750, a key asset of Centessa Pharmaceuticals, is highlighted by its promising clinical profile. The drug’s preclinical and human volunteer data suggest a broad therapeutic index and a flexible Phase 2a design, which positions it to learn from competitors and optimize dosing for pivotal trials.
Additionally, ORX750 is projected to achieve significant market growth, potentially exceeding $1.8 billion by 2030 and $3.0 billion by 2035, due to its ability to offer tailored dosing across multiple indications. Furthermore, Centessa is strategically poised to expand the application of this drug class beyond its initial indications, tapping into opportunities in neurodegenerative and neuropsychological disorders. The anticipated data from Phase 2a trials for ORX750 and human volunteer studies for ORX142 in 2025 are expected to further validate and de-risk Centessa’s platform, supporting a positive outlook for the company’s stock.

In another report released on May 20, Piper Sandler also maintained a Buy rating on the stock with a $38.00 price target.